PHILADELPHIA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating NantKwest, Inc. (“NantKwest”) (NASDAQ: NK) on behalf of the company’s shareholders.

On December 21, 2020, NantKwest announced that it had entered into an agreement to merge with ImmunityBio, a privately-held company, in a stock-for-stock transaction. Under the terms of the proposed agreement, ImmunityBio shareholders will receive a fixed exchange ratio of 0.8190 shares of NantKwest for each share of ImmunityBio stock owned, and upon completion of the merger, existing NantKwest shareholders will only own approximately 28% of the combined company.

The investigation seeks to determine whether the transaction as structured is fair to NantKwest shareholders, and whether NantKwest’s officers and/or directors breached their fiduciary duties in connection with the proposed transaction.

NantKwest shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.) at (484) 258 – 1585, or by email at skaskela@kaskelalaw.com or online at https://kaskelalaw.com/case/nantkwest-inc/, for additional information about this investigation and their legal rights and options.

Kaskela Law LLC represents investors in securities fraud, corporate governance, and merger & acquisition litigation. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.

CONTACT:

D. Seamus Kaskela, Esq.
KASKELA LAW LLC
18 Campus Boulevard, Suite 100
Newtown Square, PA 19073
(484) 258 – 1585
skaskela@kaskelalaw.com
www.kaskelalaw.com

This notice may constitute attorney advertising in certain jurisdictions.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.